Low bone density and decreased inhibin-B/FSH ratio in a boy treated with imatinib during puberty

Lancet. 2008 Jul 12;372(9633):111-112. doi: 10.1016/S0140-6736(08)61023-5.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Benzamides
  • Bone Density / drug effects*
  • Child
  • Follicle Stimulating Hormone / blood
  • Gynecomastia / chemically induced
  • Humans
  • Imatinib Mesylate
  • Inhibins / blood
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Male
  • Piperazines / adverse effects
  • Piperazines / therapeutic use*
  • Puberty / drug effects*
  • Pyrimidines / adverse effects
  • Pyrimidines / therapeutic use*

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Pyrimidines
  • inhibin B
  • Inhibins
  • Imatinib Mesylate
  • Follicle Stimulating Hormone